In January 2026, the U.S. Supreme Court decided to hear the case of Hikma v. Amarin, marking the peak of the dispute surrounding the "infringement by label" theory. The core of thistheoryis that even if generic drugs have legally "carved out" the patented uses from their labels, generic drug manufac

Huadong Medicine continued to appealed after losing the first instance. On the evening of February 26, according to the announcement of Jolly Pharmaceutical that due to the patent dispute involving Bailin, the plaintiff, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd had formally appealed to the

According to a joint decision by the China National Intellectual Property Administration (CNIPA) and the Austrian Patent Office (ÖPA), the China–Austria Patent Prosecution Highway (PPH) pilot program will be extended for another five years, from March 1, 2026, to February 28, 2031. The requirements

On January 26, 2026, Tulip Innovation Kft. announced that its patent infringement investigation targeting Chinese battery manufacturer Sunwoda and its client Geely Auto Group, initiated in South Korea, has been formally accepted by the Korea Trade Commission (KTC), showing Tulip patent pools expansi

From 2021 to 2025, the number of overseas patent publications in Chinas automotive industry increased by 94.82%, reaching a total of 21,200. In terms of technological composition, new energy vehicles and intelligent connected vehicles accounted for more than 80% of the total. Among them, power batte